BCR/ABL amplification in CML blast crisis following STI571 administration.

被引：0

作者：

Campbell, LJ

Patsouris, C

Rayeroux, KC

Somana, K

Januszewicz, H

机构：

[1] St Vincents Hosp, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia

[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia

来源：

BLOOD | 2001年 / 98卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4435

引用

页码：185B / 185B

页数：1

共 50 条

[21] Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571 [J].

Nimmanapalli, R ;

Bhalla, K .

ONCOGENE, 2002, 21 (56) :8584-8590

[22] The rationale engineering of BCR/ABL blockers: an answer to STI571 acquired resistance in leukemia treatment [J].

Majsterek, IJ .

LEUKEMIA RESEARCH, 2005, 29 (06) :605-606

[23] STI571 removal induces apoptosis in BaF/BCR-ABL resistant cell lines [J].

Desplat, V ;

Belloc, F ;

Lagarde, V ;

Melo, JV ;

Reiffers, J ;

Mahon, FX .

7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, :123-127

[24] Clinical activity of an ABL-tyrosine kinase inhibitor (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. [J].

Wassmann, B ;

Scheuring, U ;

Thiede, C ;

Bornhäuser, M ;

Griesinger, F ;

Petershofen, E ;

Gschaidmeier, H ;

Capdeville, R ;

Hoelzer, D ;

Ottmann, OG .

BLOOD, 2000, 96 (11) :218B-218B

[25] Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571 [J].

Tabrizi, R ;

Mahon, FX ;

Makhoul, PC ;

Lagarde, V ;

Lacombe, F ;

Berthaud, P ;

Melo, JV ;

Reiffers, J ;

Belloc, F .

LEUKEMIA, 2002, 16 (06) :1154-1159

[26] Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571 [J].

R Tabrizi ;

FX Mahon ;

P Cony Makhoul ;

V Lagarde ;

F Lacombe ;

P Berthaud ;

JV Melo ;

J Reiffers ;

F Belloc .

Leukemia, 2002, 16 :1154-1159

[27] Effects of Glivec® (fomerly STI571) alone and in combination with α-IFN and Ara-C on the amount of BCR/ABL transcript in CML cells. [J].

Ottaviani, E ;

Giannini, B ;

Amabile, M ;

Martinelli, G ;

Bonifazi, F ;

Zardini, C ;

Grafone, T ;

Trabacchi, E ;

Bassi, S ;

Rosti, G ;

Terragna, C ;

Buonamici, S ;

Soverini, S ;

De Vivo, A ;

Alberti, D ;

Tura, S ;

Baccarani, M .

BLOOD, 2001, 98 (11) :265B-265B

[28] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response to STI571 in chronic phase CML patients. [J].

Merx, K ;

Kreil, S ;

Lahaye, T ;

Müller, MC ;

Paschka, P ;

Schoch, C ;

Weisser, A ;

Kuhn, C ;

Landmann, T ;

Gschaidmeier, H ;

Berger, U ;

Hehlmann, R ;

Hochhaus, A .

BLOOD, 2001, 98 (11) :846A-847A

[29] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML) [J].

Thiele J. ;

Kvasnicka H.M. ;

Varus E. ;

Kriener S. ;

Engels K. ;

Staib P. ;

Ollig E.S. ;

Griesshammer M. ;

Waller C.F. ;

Pfeifer H. ;

Schmitt-Gräff A. .

Der Pathologe, 2004, 25 (6) :428-435

[30] Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines [J].

Weisberg, E ;

Griffin, JD .

BLOOD, 2000, 95 (11) :3498-3505

← 1 2 3 4 5 →